Introduction
============

Acute exacerbations of COPD (AECOPD) are caused by a variety of etiological factors.[@b1-copd-14-311] In AECOPD, the major drivers are respiratory tract infections; however, in roughly 30% of cases no clear inciting factor is found.[@b2-copd-14-311] An autopsy study of COPD patients who died within 24 hours of hospital admission due to AECOPD demonstrated that acute heart failure and pulmonary embolism were common primary causes of death.[@b3-copd-14-311] These data highlighted the importance of phenotyping AECOPD to target and treat underlying causes of AECOPD. According to the latest GOLD document,[@b4-copd-14-311] sputum cultures are generally not considered useful for guiding initial antibiotic choice or in phenotyping AECOPD. This is because sputum cultures have relatively poor sensitivity in identifying respiratory pathogens and determining therapeutic responsiveness to antimicrobials.[@b5-copd-14-311] Therefore, AECOPD are empirically treated with antibiotics and/or systemic corticosteroids, irrespective of the microbial or nonmicrobial drivers.[@b4-copd-14-311] The advent of molecular diagnostics in sputum has significantly increased the sensitivity of pathogen detection compared with traditional culture-based methods. However, its role in the prognosis or management of AECOPD has not been well defined.

In this study, our primary aim was to phenotype severe AECOPD by using a molecular pathogen-detection method. We hypothesized that a nucleic acid-based assay for detecting pathogens in sputum would enable classification of AECOPD into viral, bacterial, and uninfectious groups, which in turn would be associated with different health outcomes.

Methods
=======

Study patients
--------------

This study consisted of patients who were able to provide adequate sputum samples in the COPD Rapid Transition Program. This program's cohort has been described in detail previously.[@b6-copd-14-311],[@b7-copd-14-311] In brief, all patients included in this study were hospitalized with a confirmed primary diagnosis of AECOPD by board-certified general internists or pulmonologists who cared for these patients. All diagnoses were validated through a detailed chart review by at least one additional pulmonologist using the criteria recommended by the GOLD committee.[@b4-copd-14-311] Samples were classified as being adequate sputum samples based on color, transparency, and viscosity by study personnel, who were blinded to characteristics of the study patients. All patients received standard antiexacerbation therapy, including prednisone and antibiotics. The study is registered with [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT02050022, registered January 28, 2014). The study was approved by the University of British Columbia Providence Health Care Research Ethics Board (certificate H11-00786) for patients enrolled at St Paul's Hospital, Vancouver, Canada and the University of British Columbia Clinical Research Ethics Board (certificate H13-00790) for patients enrolled at Vancouver General Hospital, Vancouver, Canada.

Specimens and measurement technique
-----------------------------------

Following receipt of written informed consent from patients, blood samples were collected in PaxGene, EDTA, and serum tubes on days 1 and 3 of hospitalization, at discharge, and on days 30 and 90 postdischarge. Blood components were processed as per standardized protocol and stored at −80°C until analysis. N-terminal prohormone brain natriuretic peptide (NT-proBNP), CRP, and complete blood count and differentials were measured using standard techniques ([Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}).

Spontaneously expectorated sputum samples were collected on day 1 in OmniGene oral (OM505) tubes and stored in −80°C freezers until measurement. The tubes were thawed in a hot bath at 50°C for 1 hour and then placed in an air incubator at 24°C for 30 minutes. Next, Sputolysin was added in a 1:1 ratio to liquefy the samples, after which samples were subaliquoted into 500 μL volumes and stored at −80°C. Bacterial load was quantified ([Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}), and for detecting pathogenic microorganisms, the Randox Respiratory Multiplex Array II was used. This array detects 22 common bacterial and viral pathogens within 6 hours using nucleic acids extracted from sputum samples ([Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}). In brief, the assay combines multiplex PCR and biochip-array hybridization. Baseline lung-function measurements were performed at the time of convalescence (ie, at day 30 or day 90) for AECOPD patients. Spirometry was used to obtain lung-function parameters after bronchodilator administration during clinical stability according to recommendations from American Thoracic Society--European Respiratory Society guidelines.[@b8-copd-14-311]

Statistical analysis
--------------------

Continuous variables that were normally distributed are reported as mean ± SD, abnormally distributed variables as medians and IQR, and categorical variables as percentages. Continuous variables that were not normally distributed were log~10~-transformed prior to application of a parametric test where appropriate. Student's *t*-test and Mann--Whitney--Wilcoxon tests were used to determine differences between the pathogen-negative and pathogen-positive groups, and ANOVA and Kruskal--Wallis tests were used to determine differences between pathogen-negative, virus, and bacteria groups. Fisher's exact test was used to test for differences in categorical variables between the groups. Comparisons of 1-year mortality rate across groups were analyzed by Kaplan--Meier survival curves using a log-rank test, and a Cox proportional-hazard model adjusted for age and sex was used to calculate HRs. Statistical tests were two-sided, and significance was assigned to results with *P*\<0.05.

Ethics approval and consent to participate
==========================================

The study is registered with [ClinicalTrials.gov](http://ClinicalTrials.gov) (NCT02050022, registered January 28, 2014). The study was approved by the University of British Columbia Providence Health Care Research Ethics Board (certificate H11-00786) for patients enrolled at St Paul's Hospital, Vancouver, Canada and the University of British Columbia Clinical Research Ethics Board (certificate H13-00790) for patients enrolled at Vancouver General Hospital, Vancouver, Canada. Written informed consent was obtained from all enrolled patients. The study was conducted in accordance with the Declaration of Helsinki.

Results
=======

Patient characteristics
-----------------------

Demographic and clinical data for the 72 patients studied are displayed in [Table 1](#t1-copd-14-311){ref-type="table"}. Patients had a mean age of 65.8±11.5 years, 63.9% were male, 80.6% were Caucasian, and 61.1% were current smokers. All patients had airflow limitation, with mean FEV~1~ of 46.6%±16.7% predicted, and 38.9% had a history of cardiac comorbidities (heart failure, coronary artery disease, myocardial infarction, and arrhythmia).

Pathogens detected
------------------

Pathogens that were detected in our 72-patient cohort are presented in [Table 2](#t2-copd-14-311){ref-type="table"}. The most common pathogen was *Haemophilus influenzae*, accounting for 33.7% of all pathogens detected. Rhinovirus was the most common virus detected, accounting for 13.3% of all pathogens detected. Details on the pathogens detected for each patient are provided in the [Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}.

Phenotyping COPD exacerbations
------------------------------

Twenty of 72 patients (27.8%) had a negative result on the array. Nucleic acid concentrations were similar between samples that did and did not have a positive result on the array (*P*=0.71, [Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}). Patients with a negative result on the array were considered to have had an uninfectious exacerbation, whereas those who had a positive result on the array were considered to have had an infectious exacerbation. We further subdivided the patients with an infectious exacerbation into either a bacteria- or a virus-associated exacerbation based on the results. The virus group consisted of those who had a virus identified on the array, with or without detection of bacteria ([Figure 1](#f1-copd-14-311){ref-type="fig"}).

Demographics and clinical data for AECOPD exacerbations
-------------------------------------------------------

Demographic and clinical data for the groups are listed in the [Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}. There were no statistically significant differences between the pathogen-negative and pathogen-positive groups in terms of age, sex, cardiac comorbidities, inhaled corticosteroid use, or baseline FEV~1~% predicted. Of note, the pathogen-positive group was less likely to be on home (domiciliary) oxygen therapy (35% in the negative group and 14% in the positive group), but this comparison did not reach statistical significance (*P*=0.094). All hospitalizations were right-censored at 30 days, as hospital stays beyond this time frame were likely driven by factors other than AECOPD. There were no significant differences in length of hospital stay between the pathogen-negative and the pathogen-positive groups (*P*=0.096). However, a subgroup analysis revealed that there were significant differences in length of hospital stay across the bacteria, virus, and pathogen-negative groups (*P*=0.046 for overall ANOVA). These differences were largely driven by the comparison between the bacteria-associated AECOPD group and the pathogen-negative group (*P*=0.02 on post hoc analysis with Fisher's least-significant-difference test). Consistent with this analysis, there was a significant trend in length of hospitalization across the three groups, with the pathogen-negative group having the longest stay and the bacteria group having the shortest (*P*~trend~=0.017, [Figure 2](#f2-copd-14-311){ref-type="fig"}).

NT-proBNP, CRP, complete blood count, and bacterial load
--------------------------------------------------------

Concentrations of NT-proBNP, CRP, and complete blood counts for each of the groups are provided in the [Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}. We examined NT-proBNP, CRP, and complete blood counts at the date of hospital admission for all patients. The pathogen-negative group had significantly higher NT-proBNP concentrations (*P*=0.042), lower concentrations of hemoglobin (*P*=0.031), and higher red-blood-cell distribution width (*P*=0.025) compared with the pathogen-positive group ([Figure 3](#f3-copd-14-311){ref-type="fig"}). Subgroup analyses demonstrated a statistically significant difference between the pathogen-negative and virus groups for red-blood-cell distribution width (*P*=0.046 on overall Kruskal--Wallis test, Bonferroni-adjusted *P*=0.04 on post hoc pairwise comparison between the pathogen-negative and virus groups). There was no statistically significant difference among the three groups for NT-proBNP concentrations (*P*=0.081), but there was a significant trend in NT-proBNP concentrations across the three groups (*P*=0.029 on Jonckheere--Terpstra test for trend), with the pathogen-negative group having the highest concentrations and the bacteria group having the lowest ([Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}). Bacterial load measured by droplet digital PCR is shown in the [Supplementary material](#SD1-copd-14-311){ref-type="supplementary-material"}. There was no statistically significant difference between the pathogen-negative and -positive groups (*P*=0.503) or the virus and other groups (*P*=0.625). Of note, we had day 30 follow-up NT-proBNP levels in 23 patients, which showed that subjects in the negative group had a median decrease in NT-proBNP levels of 1,102 (61−1,768) ng/L, while the positive group had a median decrease of 127.5 (30−458) ng/L. However, the results did not reach statistical significance, most likely due to the small sample.

One-year mortality
------------------

Of the 72 patients included in our study, 12 died within 1 year of follow-up ([Table 3](#t3-copd-14-311){ref-type="table"}). On Kaplan--Meier survival analysis, there were no statistically significant differences between the pathogen-negative and -positive groups (*P*=0.065, [Figure 4A](#f4-copd-14-311){ref-type="fig"}). There were no statistically significant differences in survival between the virus and pathogen-negative groups (*P*=0.262), or between the virus and bacteria groups (*P*=0.376). However, there was moderate evidence of a difference in survival between the pathogen-negative and bacteria groups, which did not reach the predefined level of statistical significance (*P*=0.053, [Figure 4B](#f4-copd-14-311){ref-type="fig"}). Across the three groups, there was a trend toward increased mortality in the pathogen-negative group compared with the bacteria group (*P*=0.052). On the Cox proportional-hazard model adjusting for age and sex ([Table 4](#t4-copd-14-311){ref-type="table"}), the pathogen-negative group was approximately 4.7 times more likely to die than the bacteria group during the 1-year follow-up period (HR 4.69, 95% CI 0.92--23.8).

Discussion
==========

To our knowledge this is the first study to examine the utility of a molecular method for pathogen detection in AECOPD for the purpose of phenotyping exacerbations. Here, we showed that one in four patients hospitalized for AECOPD did not have detectable (common) respiratory pathogens in their sputum, one in three demonstrated a potential viral pathogen, and the rest had potential bacterial pathogens detected in their sputum. Most importantly, we showed that patients with a negative sputum-pathogen-array test had worse outcomes, including longer stays in hospital and a trend toward increased 1-year mortality. Interestingly, the group that demonstrated only bacteria in their sputum had the best outcomes, including the shortest hospital stay.

In this study, we demonstrated the feasibility of using molecular pathogen-detection methods that have been proven to be more sensitive in detecting viral pathogens than culture and serology methods in patients with serious AECOPD.[@b9-copd-14-311] Multiple studies have shown that molecular methods have higher sensitivity in detecting pathogens compared to traditional culture-based methods.[@b10-copd-14-311]--[@b12-copd-14-311] Moreover, molecular methods enable simultaneous detection of multiple microorganisms, including both viral and bacterial pathogens, from a single clinical specimen. This approach, known as multiplexing, is increasingly being utilized for the diagnosis of a variety of different infectious diseases, and currently, there are multiple US Food and Drug Administration-approved panels designed to aid in the diagnosis of respiratory, gastrointestinal, and central nervous system infections.[@b13-copd-14-311] A strength of our study is that we chose a clinically approved panel that detects common respiratory pathogens. This enabled us to use a single clinical specimen, in contrast to other studies, which have used different tests and different sampling sites (ie, nasopharyngeal swabs for viruses, blood and urine samples for atypical bacteria, and sputum for typical bacteria).[@b14-copd-14-311]--[@b17-copd-14-311] The pathogens detected in our study are consistent with the published literature on AECOPD in terms of type and prevalence.[@b18-copd-14-311]

The current paradigm of AECOPD pathogenesis suggests that roughly 80% of cases are infectious in origin,[@b15-copd-14-311],[@b19-copd-14-311] with a third being caused by viruses[@b20-copd-14-311] and the remainder being attributed to multiple uninfectious etiologies. Uninfectious exacerbations in COPD are frequently attributed to heart failure,[@b21-copd-14-311] atrial fibrillation,[@b22-copd-14-311] gastroesophageal reflux disease,[@b23-copd-14-311] and acute pulmonary embolism.[@b24-copd-14-311] Here, we showed that patients with a negative result on the array had higher NT-proBNP concentrations, which suggests that these patients may have experienced acute cardiac dysfunction.[@b25-copd-14-311],[@b26-copd-14-311] This raises the possibility that at least in a subset of patients with serious AECOPD, cardiac dysfunction may play a significant role in their AECOPD.

We did not observe any significant differences in CRP concentrations across groups. Several explanations are possible for this observation. First, we had a relatively small sample, which may have limited our ability to detect statistically significant differences in CRP concentrations. Second, the array does not cover all the bacterial organisms that are associated with AECOPD. Most notably, *Staphylococcus aureus* and *Pseudomonas aeruginosa* are not on this array. Therefore, patients with these infectious organisms may have been overlooked and included in the pathogen-negative group. We did not find any significant differences in CRP concentrations between viral and bacterial groups either, which have been previously noted by other groups.[@b27-copd-14-311],[@b28-copd-14-311]

In AECOPD, there are specific treatments for bacterial infections that have very high cure rates, while in the case of viral infections, influenza is the only respiratory virus that has an available treatment.[@b29-copd-14-311] We showed here that patients who had only bacteria detected in their sputum had the shortest hospitalization, while interestingly patients who had a negative result on the array had the longest hospitalization. Previous studies have shown that patients with a high burden of comorbidities, such as anemia, have longer hospitalizations for AECOPD, independently of age, sex, or FEV~1~.[@b30-copd-14-311] Similarly, those who have elevated NT-proBNP concentrations on admission also experience longer hospitalizations for their AECOPD.[@b6-copd-14-311]

Interestingly, we observed a trend toward a higher 1-year mortality rate in patients who were part of the pathogen-negative group compared to the bacteria group. The pathogen-negative group was fourfold more likely to die within 1 year of follow-up than the bacteria group. The most common causes of death in COPD patients according to death-certificate data are cardiac diseases,[@b31-copd-14-311] and elevated NT proBNP concentrations are strongly associated with mortality in AECOPD,[@b6-copd-14-311],[@b32-copd-14-311] which might explain the increased mortality rate observed in patients who had a negative result on the array.

There are several limitations to our study and studies utilizing molecular methods of pathogen detection in general. First, we used a qualitative diagnostic method, and colonization could have led to false-positive results.[@b33-copd-14-311] Colonization rates may also be increased in those with concomitant bronchiectasis, though in our study all patients had chest imaging and those with significant bronchiectasis were excluded from the study (data not shown). Second, we used sputum samples to phenotype exacerbations. However, a sputum sample does not necessarily represent the whole lung. Moreover, there are regional differences in detection rates of bacterial pathogens within the same lung.[@b34-copd-14-311],[@b35-copd-14-311] Third, our study was a retrospective study in which stored sputum samples in −80°C were tested for respiratory pathogens, and the effects of prolonged storage at low temperatures on microbial pathogen detection have not been systematically studied.[@b36-copd-14-311] However, in a study that examined the ability of the Xpert *Mycobacterium tuberculosis*--resistance to rifampicin assay to detect *M. tuberculosis* in sputum samples that had been stored in −80°C freezers for up to 4 years, the assay showed sensitivity of 95.7%, which was within the range reported in fresh samples.[@b37-copd-14-311] Another study that examined microbial communities in stored bronchoalveolar lavage samples for cystic fibrosis patients in −80°C for \>5 years showed results that were consistent with historical culturing results.[@b38-copd-14-311] Fourth, a limitation of the array is that it does not cover all pathogenic organisms implicated in AECOPD, and of these, *P. aeruginosa* and *S. aureus* are the most notable. For *Staphylococcus*, as with other organisms that possess thick cell walls, specialized DNA-extraction methods are required.[@b39-copd-14-311]--[@b42-copd-14-311] If these methods are used, it has been shown that increased detection of *Staphylococcus* comes at the expense of microbial organisms with a fragile cell wall and viruses.[@b43-copd-14-311],[@b44-copd-14-311] Currently, there is no commercial nucleic acid-extraction kit that can simultaneously extract Gram-positive, Gram-negative, and viruses from the same sample. Kajiura et al[@b44-copd-14-311] proposed a method for achieving this goal through techniques that prevent the loss of smaller viral particles while still extracting Gram-positive bacteria. This has been successfully used on 300 archived clinical samples of respiratory origin. This method appears promising, and if externally and prospectively validated, it could become the gold standard for nucleic acid extraction for molecular pathogen detection. Fifth, we did not have data on whether the subjects had received antibiotics or systemic steroids prior to presenting to our emergency department. Sixth, the small sample of the study may be a potential reason for not uncovering statistically significant outcomes. Lastly, we did not have echocardiography data to confirm with the elevated NT-proBNP concentrations the evidence of cardiac dysfunction in the pathogen-negative group.

Conclusion
==========

Comprehensive molecular methods of pathogen detection are soon to be considered a cornerstone for diagnosing respiratory infectious diseases. Molecular diagnostic methods are significantly faster and more sensitive than culture methods, and not affected by prior antibiotic use to the same extent as culture methods. One important aspect is that these methods are not only capable of simultaneously detecting a wide gamut of different pathogens (bacteria, viruses, and fungi) but also are capable of simultaneously and accurately detecting antibiotic-resistance genes.[@b45-copd-14-311] We show here that a commercially available respiratory multiplex array could aid in phenotyping AECOPD into infectious or uninfectious exacerbations. These results are encouraging to explore further and develop better molecular pathogen-detection panels that possess broader pathogen coverage and address the issue of colonization. Prospectively examining respiratory multiplex arrays in AECOPD that requires hospital admission and assessing the point-of-care advantages that these panels might possess would be the logical next step to validate their value in the utilization of hospital resources and clinical outcomes.
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![AECOPD-phenotype pie charts.\
**Notes:** Bacteria: patients who had a positive result for bacterial organisms; Virus: patients who had a positive result for viral organisms either independently or with bacterial organisms. (**A**) Patients divided by having either a negative or a positive result; (**B**) positive group subdivided by viral detection.\
**Abbreviation:** AECOPD, acute exacerbations of chronic obstructive pulmonary disease.](copd-14-311Fig1){#f1-copd-14-311}

![Box plots depicting length of hospital stay in the three groups.\
**Note:** The pathogen-negative group had longer hospitalization than the bacteria group (*P*=0.02), and a significant linear trend was present demonstrating that length of hospital stay decreased from the pathogen-negative group to the bacteria group (*P*=0.017).](copd-14-311Fig2){#f2-copd-14-311}

![Box plots depicting the significantly different variables between groups.\
**Notes:** Significant differences were present in NT-proBNP (*P*=0.042), hemoglobin (*P*=0.031), and RDW (*P*=0.025) between the pathogen-negative and -positive groups.\
**Abbreviations:** NT-proBNP, N-terminal prohormone brain natriuretic peptide; RDW, red-blood-cell distribution width. \*Represents an extreme outlier, \>3× the IQR from a quartile. °Outliers with values between 1.5--3 box lengths from the upper or lower edge of the boxplot.](copd-14-311Fig3){#f3-copd-14-311}

![Kaplan--Meier survival-analysis curves for 1-year mortality according to panel groups. **Notes:** (**A**) According to negative or positive result; (**B**) positive group subdivided by viral detection.](copd-14-311Fig4){#f4-copd-14-311}

###### 

Demographic and clinical characteristics of study patients

                                   All patients (n=72)
  -------------------------------- ---------------------
                                   
  Age (years)                      65.8±11.5
  Male sex                         63.9%
  BMI (kg/m^2^)                    24.6±7
  Caucasian                        80.6%
  Current smokers                  61.1%
  Cardiac comorbidities            38.9%
  Home oxygen use                  19.4%
  ICS use                          69.4%
  eGFR (mL/min/1.73 m^2^)          80.8±25.4
  FEV~1~% predicted                46.6±16.7
  NT-proBNP (ng/L)                 463 (217--1,295)
  CRP (mg/L)                       48.1 (16.6--116)
  Length of hospital stay (days)   6 (3.25--9)

**Note:** Data presented as percentages, mean ± SD, or medians and IQR.

**Abbreviations:** BMI, body-mass index; eGFR, estimated glomerular filtration rate; ICS, inhaled corticosteroids; NT-proBNP, N-terminal prohormone brain natriuretic peptide.

###### 

Pathogens detected on the panel

                                  Total count   \%
  ------------------------------- ------------- ------
                                                
  *Haemophilus influenzae*        28            33.7
  *Streptococcus pneumoniae*      22            26.5
  Rhinovirus                      11            13.3
  Influenza A virus               6             7.2
  Influenza B virus               3             3.6
  Respiratory syncytial virus A   3             3.6
  *Moraxella catarrhalis*         2             2.4
  Parainfluenza virus 4           2             2.4
  Coronavirus                     2             2.4
  Adenovirus                      1             1.2
  Metapneumovirus                 1             1.2
  Parainfluenza virus 2           1             1.2
  Parainfluenza virus 3           1             1.2
  Total                           83            100

###### 

Survival characteristics of AECOPD phenotypes

             Number of cases   Number of events   Number censored   Mean survival time, days (95% CI)
  ---------- ----------------- ------------------ ----------------- -----------------------------------
                                                                    
  Negative   20                6                  14 (70%)          292 (236--348)
  Positive   52                6                  46 (88.5%)        329 (303--356)
  Negative   20                6                  14 (70%)          292 (236--348)
  Virus      26                4                  22 (84.6%)        317 (273--360)
  Bacteria   26                2                  24 (92.3%)        342 (311--372)

**Abbreviation:** AECOPD, N-terminal prohormone brain natriuretic peptide.

###### 

Cox proportional-hazard model comparing the pathogen-negative, virus, and bacteria groups

  −2 log likelihood   *χ*^2^   *df*   *P*-value   *P*-value   HR      95% CI   
  ------------------- -------- ------ ----------- ----------- ------- -------- -----------
                                                                               
  Age                 −0.007   0.03   0.07        1           0.785   0.99     0.9--1.05
  Sex (male)          0.4      0.6    0.4         1           0.553   1.49     0.4--5.2
  Bacteria group                      3.8         2           0.149            
  Negative group      1.5      0.8    3.5         1           0.062   4.69     0.9--23.8
  Virus group         0.7      0.9    0.8         1           0.377   2.15     0.4--11.8
